Willers Jörg, Lucchese Alberta, Mittelman Abraham, Dummer Reinhard, Kanduc Darja
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Exp Dermatol. 2005 Jul;14(7):543-50. doi: 10.1111/j.0906-6705.2005.00327.x.
Using non-self discrimination as a driving force in generating peptide immunogenicity, we have developed a computer-assisted proteomic analysis in order to identify the protein antigenic regions that have evoked humoral response. The purpose of this study was to further validate the computational analysis for melanoma-associated antigens and, at the same time, to assess the efficacy of the methodology in defining antigenic regions of autoantigens associated to autoimmune diseases. To achieve this two-fold objective, we have examined the enzyme tyrosinase, a protein that represents an important autoantigen in patients with vitiligo or melanoma. Here, we report that the antigenic linear determinant of the monoclonal antibody (Mab) T311 raised against the melanoma/vitiligo tyrosinase autoantigen is located in the low similarity 15-mer amino acid sequence tyrosinase 233-247 IPYWDWRDAEKCDIC, within the fragment 237-247. These data confirm non-similarity to the host proteome as a factor that participates in shaping peptide immune reactivity and may be a first step towards designing tyrosinase antigenic peptides to be used for (i) direct neutralization of harmful melanocytes-attacking autoantibodies in vitiligo, or (ii) production of antibodies against tyrosinase-positive melanomas. Moreover tyrosinase peptide antigens might be used as key tools in studying the boundaries between self-tolerance and autoimmunity phenomena.
我们利用非自身识别作为产生肽免疫原性的驱动力,开发了一种计算机辅助蛋白质组分析方法,以识别引发体液免疫反应的蛋白质抗原区域。本研究的目的是进一步验证针对黑色素瘤相关抗原的计算分析,并同时评估该方法在定义与自身免疫性疾病相关的自身抗原的抗原区域方面的有效性。为实现这一双重目标,我们研究了酪氨酸酶,它是白癜风或黑色素瘤患者体内一种重要的自身抗原。在此,我们报告,针对黑色素瘤/白癜风酪氨酸酶自身抗原产生的单克隆抗体(Mab)T311的抗原线性决定簇位于片段237 - 247内低相似性的15个氨基酸序列酪氨酸酶233 - 247 IPYWDWRDAEKCDIC中。这些数据证实与宿主蛋白质组的非相似性是参与塑造肽免疫反应性的一个因素,并且可能是设计酪氨酸酶抗原肽的第一步,这些抗原肽可用于:(i)直接中和白癜风中攻击有害黑素细胞的自身抗体,或(ii)产生针对酪氨酸酶阳性黑色素瘤的抗体。此外,酪氨酸酶肽抗原可能是研究自身耐受和自身免疫现象之间界限的关键工具。